#United States #Cancer Immunotherapy #National Harbor #SITC #late-breaking

The Society for Immunotherapy of Cancer's Milestone Meeting

From November 5-9, 2025, the Society for Immunotherapy of Cancer (SITC) will celebrate its monumental 40th anniversary through an event that promises to highlight the latest advancements in cancer treatment. This year's annual meeting comes after an overwhelming response, receiving over 1,300 abstract submissions that encapsulate groundbreaking research in the realm of cancer immunotherapy.

The event will be held both in-person at National Harbor, MD, and streamed online for global accessibility. It represents a pivotal opportunity not only for researchers and practitioners but also for patients and advocates seeking the latest findings in immuno-oncology. Included in this presentation will be the highly anticipated late-breaking abstracts, which encompass crucial and timely data from interventional clinical trials involving human subjects.

Exciting Announcements from SITC

SITC has officially announced the titles and authors of the selected late-breaking abstracts (LBA) that will be featured during the meeting. These abstracts address a wide range of topics crucial to cancer treatment and highlight innovative approaches that could reshape the future of cancer care. Attendees of the virtual press briefing will get the first glimpse of these remarkable findings.

Among the headlining presentations is Abstract #119, introduced by Qinqin Jiang, PhD from Dana-Farber Cancer Institute. This abstract discusses the role of endogenous retroviruses as tumor-specific antigens in clear cell renal cell carcinoma, paving the way for targeted immunotherapy.

Further enlightening discussions will be led by Jane Xie, BS from the University of Pennsylvania, who will present Abstract #748, focusing on how the tissue of origin influences immune cell heterogeneity and therapy response. This work illustrates the complexities of cancer treatment and the necessity for precision medicine.

Another crucial finding will be shared by Lilit Karapetyan, MD from Moffitt Cancer Center in Abstract #1340, highlighting how lead-in therapies targeting PD1 and LAG3 can distinctly impact immune responses in the first line of treatment against metastatic melanoma.

Clinical Insights and Advancements

The ongoing commitment to advancing clinical treatments will be evident through the diverse range of research findings presented during the meeting. Notable mentions include:

• - Abstract #366: A presentation by Christian Hinrichs, MD from Rutgers, depicting complete tumor regression in metastatic epithelial cancer following T cell receptor (TCR)-T cell therapy.
• - Abstract #1316: Aurélien Marabelle, MD, PhD from Gustave Roussy will present initial monotherapy clinical activity data for invikafusp alfa, a novel bifunctional antibody, targeting TMB-H patients from a phase 1/2 trial.
• - Abstract #1325: Highlighting the interim results of a DNA plasmid vaccine trial combined with checkpoint blockade in advanced melanoma presented by Nermeen Varawalla, MD, PhD, MBA from Scancell Ltd.

• - Abstract #1348: Final survival data analysis comparing Ivonescimab with chemotherapy in patients with EGFR-positive NSCLC will be revealed by Xiuning Le, MD, PhD from The University of Texas MD Anderson Cancer Center.

Engaging with the Research Community

Media representatives attending the pressing briefing will have the opportunity to engage directly with presenters through a question-and-answer format, facilitating a dynamic exchange of ideas. The press briefing, set to commence at 12 p.m. ET on Wednesday, November 5, 2025, will serve as a platform for sharing key insights and data that could have lasting impacts on the field of cancer treatment.

To participate, members of the press must register on SITC's website, gaining access to further instructions leading up to the event. The SITC 2025 annual meeting not only commemorates the society's rich history of accomplishments since its establishment in 1984 but also underscores its commitment to advancing the science and application of cancer immunotherapy.

For further details about SITC and upcoming initiatives, visit their official website sitcancer.org. Through these continuous efforts, SITC aims to transform the treatment landscape, bringing hope to cancer patients worldwide.